Psyence BioMed launches psilocybin longevity research program

Psyence Biomedical Ltd. (NASDAQ: PBM) announced the launch of a psilocybin longevity research initiative in collaboration with researchers in South Africa. The company stated it is the first publicly listed company to investigate psilocybin's potential impact on biological markers associated with aging and longevity.

The biopharmaceutical company, which develops nature-derived psilocybin and ibogaine therapies for mental health conditions, will conduct preclinical studies examining biomarkers related to cellular stress, inflammation, mitochondrial function, and behavioral indicators associated with healthspan and lifespan. The company has commenced the project, with full acceleration anticipated early next year following ethics approval.

The research will be led by Dr. Tanya Calvey, a neuroscientist specializing in translational neuropsychopharmacology. The company cited recent preclinical research showing that psilocin, psilocybin's active metabolite, extended survival in aged mouse models and increased the lifespan of human skin and lung cells by more than 50%.

"The scientific community is only beginning to uncover the potential links between psychedelics and longevity," said Dr. Calvey. "Psilocybin modulates inflammation, neural connectivity, and cellular stress responses – all central to how we understand aging biology."

Chief Executive Officer Jody Aufrichtig noted the initiative's timing amid growing interest in longevity science. "As the first publicly listed company actively pursuing this research, Psyence BioMed is positioned at the forefront of an entirely new therapeutic arena," Aufrichtig said.

The longevity research complements the company's ongoing clinical development programs, including a psilocybin-assisted therapy trial for existential distress in palliative care patients in Australia.

You May Also Be Interested In

• Alphabet added to Dow Jones Industrial Average, Verizon dropped
• Silvercorp GC Mine mineral resources rise 59% in updated report
• Cboe launches binary options suite tied to Mini-S&P 500 Index